In consultation: Guidance and quality standards
Showing 1 to 10 of 18
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Obinutuzumab for treating serologically active extra-renal lupus [ID6670] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160] | Review proposal consultation | Technology appraisal guidance | |
| Heart failure - sacubitril valsartan [ID822] | Review proposal consultation | Technology appraisal guidance | |
| Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826] | Review proposal consultation | Technology appraisal guidance | |
| Tirzepatide for treating type 2 diabetes [ID3938] | Review proposal consultation | Technology appraisal guidance | |
| Empagliflozin in combination therapy for treating type 2 diabetes | Review proposal consultation | Technology appraisal guidance | |
| Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158] | Review proposal consultation | Technology appraisal guidance | |
| Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962] | Review proposal consultation | Technology appraisal guidance | |
| Diabetes (type 2) - canagliflozin, dapagliflozin and empagliflozin (monotherapy) [ID756] | Review proposal consultation | Technology appraisal guidance |